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Background
Eliciting a neutralizing human antibody against HIV-1
still remains to be elusive. Nevertheless, a number of
studies have reported isolation of potent and broadly
reactive antibodies against HIV-1 from HIV-1 infected
patient serum. Antibody VRC01 is one of these kinds
that binds to the CD4 binding site of gp120 and neutra-
lizes the viruses. Recently, we identified antibody
VRC07, which is more potent and broadly reactive anti-
HIV-1 antibody than its derivative, VRC01.
Methods
In this study, we determined the crystal structure of
gp120 in complex with VRC07 and utilized mechanistic
insights and structure-guided modification to increase
potency and breadth.
Results
A four amino acid insertion in the CDR H3 loop of
VRC07 provided for more extensive contacts with gp120
than with VRC01. The structure also revealed that resi-
due Gly54 of VRC07 could be replaced with amino
acids with bulky side chains to mimic residue Phe43 of
CD4. Indeed, all VRC07 variants, in which Gly54 was
replaced with Arg, Leu, Phe, Trp, or Tyr, showed
enhanced affinity to a panel of different HIV-1 gp120s.
Furthermore, most of these Gly54 alterations showed
enhanced potency and breadth against a panel of clade
B and C viruses in TZM-bl cell-based neutralization
assay. Crystal structures of gp120 in complexes with
these VRC07 Gly54 variants confirmed that their side
chains mimicked Phe43 of CD4. Computational analysis
of the VRC07-gp120 interface in the crystal structure
identified residues Ile30 and Ser58 as likely targets for
improvement (with Gln and Asn, respectively). These
changes introduced additional hydrogen bonds to the
VRC07-gp120 interfaces and further enhanced VRC07
potency.
Conclusion
Thus, our optimization of antibody VRC07 demon-
strated that a structure-guided approach can be used to
increase both antibody potency and breath. The opti-
mized VRC07 developed here can be used as the basis
for further structure-guided improvement or for optimi-
zation via in vitro selection.
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